Genzyme gets FDA notice of additional re-inspection of US Allston plant
This article was originally published in Scrip
Executive Summary
The US FDA has informed Genzyme that it will re-inspect the company's Allston, Massachusetts manufacturing plant as a follow-up to a re-inspection that took place in May. News of yet another inspection came as a surprise to both the company and investors, as they thought all outstanding issues from the February 27th, 2009 FDA warning letter had all been addressed.